Alto Neuroscience, Inc. (NYSE:ANRO) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Alto Neuroscience, Inc. (NYSE:ANRO) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $35.25.

Several equities research analysts have recently weighed in on ANRO shares. HC Wainwright reissued a “buy” rating on shares of Alto Neuroscience in a research note on Wednesday, June 17th. Wolfe Research started coverage on shares of Alto Neuroscience in a research report on Friday, May 22nd. They issued an “outperform” rating for the company. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price objective on the stock. Robert W. Baird cut their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Monday, May 18th. Finally, Zacks Research lowered shares of Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, July 22nd.

Alto Neuroscience Trading Down 0.2%

ANRO opened at $28.61 on Monday. The stock has a market capitalization of $1.00 billion, a PE ratio of -11.82 and a beta of 1.06. The firm’s fifty day moving average price is $24.87 and its 200 day moving average price is $22.33. The company has a debt-to-equity ratio of 0.07, a current ratio of 20.52 and a quick ratio of 20.52. Alto Neuroscience has a 12-month low of $3.02 and a 12-month high of $29.49.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, research analysts expect that Alto Neuroscience will post -3.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Alto Neuroscience

Institutional investors have recently made changes to their positions in the business. Commodore Capital LP grew its holdings in Alto Neuroscience by 49.4% in the 1st quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after buying an additional 900,000 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Alto Neuroscience by 161.6% during the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after buying an additional 1,535,000 shares during the last quarter. Perceptive Advisors LLC boosted its position in shares of Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock valued at $45,182,000 after acquiring an additional 225,500 shares during the period. Armistice Capital LLC boosted its position in shares of Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after acquiring an additional 12,000 shares during the period. Finally, Spruce Street Capital LP grew its stake in shares of Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock worth $29,116,000 after acquiring an additional 1,102,366 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.